Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis
* Vermeulen M.
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Neurologie, Postbus 22.660, II00 DD Amsterdam.. email@example.com
Immunomodulatory therapy reduces the rate of relapse in multiple sclerosis (MS) by 30% in the first year of treatment; the effect in the second year is uncertain. Relapse is caused by the effects of inflammation ...